Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04750681
Other study ID # Saffractiv2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2019
Est. completion date November 3, 2020

Study information

Verified date January 2021
Source Comercial Quimica Masso, S.A
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Therefore, the aim of this study was to confirm by a randomized double-blind controlled study the beneficial effects of saffron extract (Saffr'activ®) on sleep quality in subjects presenting mild to moderate sleep disorder associated with anxiety.


Description:

This study has been designed as a randomized double-blind placebo-controlled interventional study. Sixty-six subjects were randomly allocated to the control (placebo) or test (Saffr'activ®) group. A screening visit was scheduled within 4 weeks before Day -7 (study inclusion). At Day -7 and Day 0, questionnaires were completed to evaluate sleep quality, stress level and quality of life. Between Day -7 and Day 0 baseline data for actimeter and sleep diary were registered. Then, subjects were supplemented during 6 weeks with the placebo or saffron (Saffr'activ®) product, depending on their group. Following the baseline period, two other periods of one week were scheduled to collect actigraphy data: between 2 and 3 (from Day 14 to Day 21) weeks and between 5 and 6 (from Day 35 to Day 42) weeks after the beginning of the intervention. At the middle (Day 21) and at the end of the study (Day 42), questionnaires were completed to evaluate sleep quality, stress level and/or quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date November 3, 2020
Est. primary completion date November 3, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: - In good general health as evidenced by medical history and physical examination; - Presenting mild to moderate chronic primary sleep disorder (evaluated by Insomnia Severity Index - ISI, score between 7 and 21); - Presenting mild to moderate anxiety (evaluated by Perceived Stress Scale - PSS, score between 6 and 29); - For women: use of effective contraception; - Fluent French speaking; - Provision of signed and dated informed consent form; - Stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: - Sleep disorders secondary to another health problem; - Lifestyle habits which would modify the wake-sleep rhythm (e.g. night work) or which would be modified during the study period; - Pharmacological resistance to common hypnotic drugs or consumption of hypnotic drugs (< 3 months before the inclusion); - Subjects presenting gastro-intestinal, hepatic, respiratory, psychiatric, kidney or cardiovascular disorders (< 3 months before the inclusion); - Abnormal blood sampling; - Subjects presenting depressive disorder (BDI score > 30); - Recent (< 3 months before the inclusion) change in lifestyle (food, body weight > 5kg, sport); - Within 3 months before the inclusion, chronic (> 7 days in a row) intake or dosage change of drug(s) or food supplement(s); - Addict subjects or with historical addiction; - Subjects who drink more than 3 glasses of alcohol per day (> 30g of alcohol per day); - Exaggerated consumption of theine (= 500ml per day) and caffeine-rich (= 400ml per day) beverages and energy drink (= 250ml per day); - Pregnant or lactating woman; - Known allergy to saffron and/or olives; - Subjects having participated to another clinical trial one month before the selection visit.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
Subjects orally ingested, with water, one capsule per day (in the evening)
Saffron
Subjects orally ingested, with water, one capsule per day (in the evening)

Locations

Country Name City State
Belgium UCLouvain - CICN Louvain-La-Neuve

Sponsors (2)

Lead Sponsor Collaborator
Comercial Quimica Masso, S.A Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Leeds Sleep Evaluation Questionnaire score at 42 days Questionnaire, score 0-100, higher score = better Baseline (day-7 and day 0) and day 42 (end of the study)
Secondary Change from baseline Leeds Sleep Evaluation Questionnaire score at 21 days Questionnaire, score 0-100, higher score = better Baseline (day -7 and day 0) and day 21
Secondary Pittsburgh Sleep Quality Index Questionnaire, score 0-21, higher score = worse Baseline (day -7 and day 0) and day 42 (end of the study)
Secondary Epworth Sleepiness Scale Questionnaire, score 0-24, higher score = worse Baseline (day-7 and day 0), day 21 and day 42 (end of the study)
Secondary Perceived Stress Scale Questionnaire, score 0-40, higher score = worse Baseline (day -7 and day 0) and day 42 (end of the study)
Secondary Short Form (36) Health Survey Questionnaire, score 0-100, higher score = better Baseline (day -7 and day 0) and day 42 (end of the study)
Secondary Time in bed Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
Secondary Actual sleep time Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
Secondary Wake after sleep onset Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
Secondary Sleep onset latency Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
Secondary Fragmentation index Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
Secondary Sleep efficiency Actimetry Baseline (from day -7 to day 0), third week (from day 14 to day 21), last week (from day 35 to 42)
See also
  Status Clinical Trial Phase
Completed NCT05130944 - Feasibility of Community Psychosocial Intervention for Women N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05881681 - A Mindfulness Approach to UA for Afro-descendants N/A
Recruiting NCT05449002 - Digital Single Session Intervention for Youth Mental Health N/A
Recruiting NCT04038190 - A Behavioral Activation Intervention Administered in a College Freshman Orientation Course Phase 2
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Active, not recruiting NCT05998161 - Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout N/A
Completed NCT03728062 - Mindfulness Meditation Versus Physical Exercise: Comparing Effects on Stress and Immunocompetence N/A
Terminated NCT04367636 - The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19 N/A
Completed NCT06405789 - The Effect of Yoga on Mindfulness and Perceived Stress N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT05245409 - Stress, EEG, ECG, and Chiropractic N/A
Completed NCT04722367 - Being Present With Art: The Impact of Mindful Engagement With Art on Awareness and Connection N/A
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Completed NCT06057883 - Effects Of A Probiotic Formulation On Stress and Skin Health in Younger Adult Females Phase 2
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Completed NCT05312749 - The Effect of Web Based Progressive Muscle Relaxation Exercise on Clinical Stress and Anxiety of Nursing Students N/A
Completed NCT05623826 - Feasibility and Efficacy of a Digital Training Intervention to Increase Reward Sensitivity- Imager N/A
Completed NCT04013451 - The Kiss of Kindness Study II N/A